Tremfya Market Size, Share, Trends, Industry Analysis Report By Application [Plaque Psoriasis, Psoriatic Arthritis (PsA), Others], By Distribution Channel, By Region – Market Forecast, 2025–2034
Description
The global tremfya market size is expected to reach USD 7.99 billion by 2034, according to a new study by Polaris Market Research. The report “Tremfya Market Size, Share, Trends, Industry Analysis Report By Application [Plaque Psoriasis, Psoriatic Arthritis (PsA), Others], By Distribution Channel, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The Tremfya market is centered around the global sales and distribution of guselkumab, a biologic medication. This advanced treatment specifically targets interleukin-23 (IL-23), a protein in the immune system that plays a key role in inflammatory responses. Tremfya is primarily used to manage chronic conditions such as moderate-to-severe plaque psoriasis and active psoriatic arthritis, aiming to reduce inflammation and improve patient symptoms. Recently, its use has expanded to include moderately to severely active ulcerative colitis and Crohn's disease, broadening its application and patient reach.
The Tremfya market growth is largely driven by the increasing global prevalence of these chronic inflammatory diseases. As more people are diagnosed with conditions such as plaque psoriasis and psoriatic arthritis, the demand for effective and long-term treatments continues to rise. Additionally, Tremfya's strong clinical profile, demonstrating significant efficacy in improving symptoms and quality of life for patients, is a major growth factor. Its ability to offer durable outcomes and, in some cases, inhibit disease progression, makes it a preferred option for healthcare providers and patients seeking advanced therapeutic solutions.
Tremfya Market Report Highlights:
By application, the plaque psoriasis segment held the largest share of the Tremfya market in 2024. This is mainly because plaque psoriasis affects a large number of people worldwide, and Tremfya has shown strong results in helping patients achieve clear or almost clear skin.
By distribution channel, the hospital pharmacies segment held the largest share in 2024. This is due to the rising need for specialized handling and administration of biologic drugs, often performed in hospital settings, and the fact that specialists who prescribe these complex treatments are frequently based in hospitals.
By region, North America held the largest share in 2024. This dominance is driven by the high prevalence of target diseases in the region, a well-developed healthcare infrastructure that supports advanced biologic therapies, and a generally higher willingness to adopt innovative and often high-cost treatments. Asia Pacific is an emerging and rapidly expanding market for Tremfya. While the prevalence of chronic inflammatory diseases may historically have been perceived as lower in some parts of this region, increasing urbanization, lifestyle changes, and improved diagnostic capabilities are contributing to a rise in reported cases.
Johnson & Johnson is the current manufacturer of Tremfya.
Polaris Market Research has segmented the Tremfya market report based on application, distribution channel, and region:
By Application Outlook (Revenue – USD Billion, 2020–2034)
Plaque Psoriasis
Psoriatic Arthritis (PsA)
Others
By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
The Tremfya market is centered around the global sales and distribution of guselkumab, a biologic medication. This advanced treatment specifically targets interleukin-23 (IL-23), a protein in the immune system that plays a key role in inflammatory responses. Tremfya is primarily used to manage chronic conditions such as moderate-to-severe plaque psoriasis and active psoriatic arthritis, aiming to reduce inflammation and improve patient symptoms. Recently, its use has expanded to include moderately to severely active ulcerative colitis and Crohn's disease, broadening its application and patient reach.
The Tremfya market growth is largely driven by the increasing global prevalence of these chronic inflammatory diseases. As more people are diagnosed with conditions such as plaque psoriasis and psoriatic arthritis, the demand for effective and long-term treatments continues to rise. Additionally, Tremfya's strong clinical profile, demonstrating significant efficacy in improving symptoms and quality of life for patients, is a major growth factor. Its ability to offer durable outcomes and, in some cases, inhibit disease progression, makes it a preferred option for healthcare providers and patients seeking advanced therapeutic solutions.
Tremfya Market Report Highlights:
By application, the plaque psoriasis segment held the largest share of the Tremfya market in 2024. This is mainly because plaque psoriasis affects a large number of people worldwide, and Tremfya has shown strong results in helping patients achieve clear or almost clear skin.
By distribution channel, the hospital pharmacies segment held the largest share in 2024. This is due to the rising need for specialized handling and administration of biologic drugs, often performed in hospital settings, and the fact that specialists who prescribe these complex treatments are frequently based in hospitals.
By region, North America held the largest share in 2024. This dominance is driven by the high prevalence of target diseases in the region, a well-developed healthcare infrastructure that supports advanced biologic therapies, and a generally higher willingness to adopt innovative and often high-cost treatments. Asia Pacific is an emerging and rapidly expanding market for Tremfya. While the prevalence of chronic inflammatory diseases may historically have been perceived as lower in some parts of this region, increasing urbanization, lifestyle changes, and improved diagnostic capabilities are contributing to a rise in reported cases.
Johnson & Johnson is the current manufacturer of Tremfya.
Polaris Market Research has segmented the Tremfya market report based on application, distribution channel, and region:
By Application Outlook (Revenue – USD Billion, 2020–2034)
Plaque Psoriasis
Psoriatic Arthritis (PsA)
Others
By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
120 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
